EGFR and neoplasm: Based on an ectopic EGFR expression model, cancer cell lines expressing various EGFR mutants, and a tumor xenograft model, we found that erlotinib inhibits EGFR phosphorylation across the models, but protein degradation is induced only in the case of erlotinib responsive cells, which correlates with the response.